

Clinical trials of gliclazide

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
gliclazide vs nateglinide (add on MET)			
Ristic , 2006 n=NA follow-up: 52 weeks	gliclazide plus metformin versus nateglinide plus metformin	-	double-blind
gliclazide vs pioglitazone (add on MET)			
Matthews , 2005 n=313/317 follow-up: 52 weeks	gliclazide 80 mg o.d. (titrated up to 320 mg versus pioglitazone 15 mg o.d. (titrated up to 45 mg	Patients with poorly controlled type 2 diabetes	double-blind
gliclazide vs rosiglitazone (add on MET)			
Khanolkar , 2008 n=NA follow-up: 24 weeks	metformin and gliclazide versus metformin and rosiglitazone	-	

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- insulin secretagogues - sulfonylureas for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q483>

References

Ristic, 2006:

Ristic S, Collober-Maugeais C, Pecher E, Cressier F Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med 2006;23:757-62 [[16842480](#)] [10.1111/j.1464-5491.2006.01914.x](#)

Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher E Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes Obes Metab 2007;9:506-11 [[17587393](#)] [10.1111/j.1463-1326.2006.00632.x](#)

Matthews, 2005:

Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Scherthaner G Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-74 [[15386821](#)] [10.1002/dmrr.478](#)

Khanolkar, 2008:

Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, Evans LM Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—an effect probably mediated by direct platelet PPARgamma activation. *Atherosclerosis* 2008;197:718-24 [17765245] [10.1016/j.atherosclerosis.2007.07.020](https://doi.org/10.1016/j.atherosclerosis.2007.07.020)

Entry terms: Gliclazide, Glyclazide, Gliklazid, Diamicron, S-1702, S 1702, S1702, S-852, S 852, S852, Diaglyk, Gen-Gliclazide, Gen Gliclazide, Glyade, Novo-Gliclazide, Novo Gliclazide, Diaikron, Diabrezide,